Skip to Main Content

Author Details

Dariush Etemadmoghadam
Peter MacCallum Cancer Centre
2004
40
29
PMIDPaper TitleJournal TitlePublished Year
36720497Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.J Immunother Cancer2023
37012077The Colorectal cancer RISk Prediction (CRISP) trial: a randomised controlled trial of a decision support tool for risk-stratified colorectal cancer screening.Br J Gen Pract2023
36720497Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.J Immunother Cancer2023
37012077The Colorectal cancer RISk Prediction (CRISP) trial: a randomised controlled trial of a decision support tool for risk-stratified colorectal cancer screening.Br J Gen Pract2023
32901952Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.J Pathol2021
32901952Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.J Pathol2021
34465787Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.NPJ Breast Cancer2021
34465787Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.NPJ Breast Cancer2021
30967419Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.Clin Cancer Res2019
30967419Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.Clin Cancer Res2019
30835257Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.J Clin Invest2019
30835257Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.J Clin Invest2019
29061645Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.Clin Cancer Res2018
35135122<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.JCO Precis Oncol2018
3020901519q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.Gynecol Oncol2018
29061645Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.Clin Cancer Res2018
35135122<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.JCO Precis Oncol2018
3020901519q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.Gynecol Oncol2018
27663592Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.Clin Cancer Res2017
28646021<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.Cancer Res2017
27663592Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.Clin Cancer Res2017
28646021<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.Cancer Res2017
25810134Efficient molecular subtype classification of high-grade serous ovarian cancer.J Pathol2015
25810134Efficient molecular subtype classification of high-grade serous ovarian cancer.J Pathol2015
26017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26503049Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26503049Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
24366882Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.Cancer Res2014
25498304AKT1 gene amplification as a biomarker of treatment response in ovarian cancer: mounting evidence of a therapeutic target.Gynecol Oncol2014
25316818Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.Clin Cancer Res2014
24366882Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.Cancer Res2014
24560445Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.Mol Oncol2014
25498304AKT1 gene amplification as a biomarker of treatment response in ovarian cancer: mounting evidence of a therapeutic target.Gynecol Oncol2014
25316818Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.Clin Cancer Res2014
24560445Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.Mol Oncol2014
23372714High levels of genomic aberrations in serous ovarian cancers are associated with better survival.PLoS One2013
24218601Synthetic lethality between CCNE1 amplification and loss of BRCA1.Proc Natl Acad Sci U S A2013
24004674Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.Clin Cancer Res2013
23633455Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.Clin Cancer Res2013
23257362Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.J Clin Invest2013
23372714High levels of genomic aberrations in serous ovarian cancers are associated with better survival.PLoS One2013
24218601Synthetic lethality between CCNE1 amplification and loss of BRCA1.Proc Natl Acad Sci U S A2013
24004674Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.Clin Cancer Res2013
23633455Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.Clin Cancer Res2013
23257362Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.J Clin Invest2013
22514011Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes.J Pathol2012
22896685LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.Cancer Res2012
22912389Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.Clin Cancer Res2012
22514011Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes.J Pathol2012
  • 1 - 50 of 80

Recommended Authors

Pier Selenica
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 4
Arnaud Da Cruz Paula
Memorial Sloan Kettering Cancer Center
Career Start Year 2014
Number of shared co-authors 2
Amy Lum
University of British Columbia
Career Start Year 2014
Number of shared co-authors 27
Robertson Mackenzie
Vancouver General Hospital, and University of British Columbia
Career Start Year 2013
Number of shared co-authors 30
Jenny Lester
David Geffen School of Medicine, University of California at Los Angeles
Career Start Year 2012
Number of shared co-authors 37
Ghassan Allo
Henry Ford Hospital
Career Start Year 2011
Number of shared co-authors 4
Chen Wang
Center for Individualized Medicine, Mayo Clinic
Career Start Year 2011
Number of shared co-authors 30
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 14
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 2
Boris Winterhoff
University of Minnesota
Career Start Year 2008
Number of shared co-authors 28
Anna M Piskorz
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2007
Number of shared co-authors 33
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 16
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 24
Leah M Prentice
British Columbia Women's Hospital and Health Centre
Career Start Year 2004
Number of shared co-authors 12
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 18
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 0
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 0
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 15
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 9
Steve E Kalloger
University of British Columbia
Career Start Year 2000
Number of shared co-authors 12
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 4
Mar??a J Garc??a
Spanish National Cancer Research Centre (CNIO)
Career Start Year 1996
Number of shared co-authors 33
Janine Senz
University of British Columbia
Career Start Year 1994
Number of shared co-authors 32
Simon A Gayther
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 35
Sandra Orsulic
David Geffen School of Medicine, University of California at Los Angeles
Career Start Year 1992
Number of shared co-authors 36
Patricia A Shaw
Princess Margaret Cancer Centre, University Avenue
Career Start Year 1990
Number of shared co-authors 23
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 4
Tanja Pejovic
Oregon Health & Science University
Career Start Year 1989
Number of shared co-authors 31
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 30
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Career Start Year 1981
Number of shared co-authors 40

Collaborators

David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 37
Anna DeFazio
Westmead Hospital
Co-authored papers 19
Joshy George
Peter MacCallum Cancer Centre
Co-authored papers 17
Sian Fereday
Peter MacCallum Cancer Centre
Co-authored papers 13
Kathryn Alsop
Peter MacCallum Cancer Centre
Co-authored papers 10
Paul Harnett
Westmead Clinical School, University of Sydney
Co-authored papers 9
Yoke-Eng Chiew
Westmead Hospital
Co-authored papers 8
George Au-Yeung
The University of Melbourne
Co-authored papers 7
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 7
Ronny Drapkin
University of Pennsylvania School of Medicine
Co-authored papers 7
Joy Hendley
Peter MacCallum Cancer Centre
Co-authored papers 6
Martin K??bel
University of Calgary
Co-authored papers 6
Nadia Traficante
Peter MacCallum Cancer Centre
Co-authored papers 6
Sean M Grimmond
The University of Melbourne
Co-authored papers 5
John V Pearson
QIMR Berghofer Medical Research Institute
Co-authored papers 5
Ann-Marie Patch
QIMR Berghofer Medical Research Institute
Co-authored papers 5
Gillian Mitchell
Familial Cancer Centre Peter MacCallum Cancer Centre Parkville Victoria 0 Australia.
Co-authored papers 5
Nicola Waddell
QIMR Berghofer Medical Research Institute
Co-authored papers 5
Michael S Anglesio
University of British Columbia
Co-authored papers 5
Raghwa Sharma
Westmead Hospital
Co-authored papers 5
Gordon K Smyth
The University of Melbourne
Co-authored papers 4
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 4
Rosemary L Balleine
Westmead Institute for Medical Research, The University of Sydney
Co-authored papers 3
Ian G Campbell
Co-authored papers 3
Alison Brand
Westmead Hospital
Co-authored papers 3
David G Huntsman
University of British Columbia
Co-authored papers 3
Douglas A Levine
Perlmutter Cancer Center
Co-authored papers 3
Euan A Stronach
Imperial College London
Co-authored papers 3
Richard B Pearson
Co-authored papers 3
Robert Brown
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 3
Release 1.2